
Roche acquires trispecific antibody for $1.5bn
Roche has acquired exclusive global rights to develop, manufacture, and commercialise SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases. Under the terms of the agreement, developer Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including $75 million in… Read More


